CXCR7‐shRNA can also suppress tumour invasion and metastasis to improve the efficacy of TACE for HCC treatment by reducing the expressions of CXCR7, MMP‐2 and VEGF. The gene discussed is ACKR3; the disease is hepatocellular carcinoma.